Drug Profile
Albumin/interferon alpha 2A fusion protein
Alternative Names: Recombinant human serum albumin/interferon alpha2a fusion proteinLatest Information Update: 16 Feb 2016
Price :
$50
*
At a glance
- Originator Beijing Bio-Fortune
- Class Albumins; Antivirals; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 16 Feb 2016 No recent reports on development identified - Phase-I/II for Hepatitis B in China (SC)
- 01 Nov 2014 Beijing Bio-Fortune completes a phase I/II trial in Hepatitis B in China (NCT01997944)
- 25 Nov 2013 Phase-I/II clinical trials in Hepatitis B in China (SC)